[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100619805":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":29,"centralContacts":29,"locations":30,"responsibleParty":44,"collaborators":29,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":29,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":54,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":29,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":29,"overallStatus":66,"whyStopped":29,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Vertex Pharmaceuticals Incorporated","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"VNZ\u002FTEZ\u002FD-IVA and Rosuvastatin","EXPERIMENTAL","Rosuvastatin will be administered to participants as a single oral dose on Day 1 and then co-administered with VNZ\u002FTEZ\u002FD-IVA on Day 18.VNZ\u002FTEZ\u002FD-IVA dose will be administered once daily (qd) from Day 5 to Day 22.",[13,14],"Drug: VNZ\u002FTEZ\u002FD-IVA","Drug: Rosuvastatin",[16,25],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"DRUG","VNZ\u002FTEZ\u002FD-IVA","Fixed-dose combination (FDC) Tablet for oral administration.",[9],[22,23,24],"Vanzacaftor\u002FTezacaftor\u002FDeutivacaftor","VX-121\u002FVX-661\u002FVX-561","VX-121\u002FVX-661\u002FCTP-656",{"type":17,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"Rosuvastatin","Tablet for oral administration.",[9],null,[31],{"facility":32,"status":29,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":29},"Altasciences - Kansas City","Overland Park","Kansas","66212","United States","US",{"type":39,"coordinates":40},"Point",[41,42],-94.67079,38.98223,{"lat":42,"lon":41},{"type":45,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR","100619805","phase-1-effect-of-vanzacaftortezacaftordeutivacaftor-vnztezd-iva-on-the-pk-of-rosuvastatin-in-healthy-participants-100619805",false,"NCT07349394","Effect of Vanzacaftor\u002FTezacaftor\u002FDeutivacaftor (VNZ\u002FTEZ\u002FD-IVA) on the PK of Rosuvastatin in Healthy Participants","A Phase 1, Open-label, Drug-Drug Interaction Study to Evaluate the Effect of Multiple Doses of Vanzacaftor\u002FTezacaftor\u002FDeutivacaftor on the Pharmacokinetics of Rosuvastatin in Healthy Subjects","Key Inclusion Criteria:\n\n* Body mass index (BMI) of 18.0 to 32.0 kilogram per meter square (Kg\u002Fm\\^2), both inclusive\n* A total body weight greater than (\\>)50 kg\n\nKey Exclusion Criteria:\n\n* History of febrile illness within 5 days before the first dose of study drug\n* Any condition possibly affecting drug absorption\n* Female participants who are pregnant, nursing, or planning to become pregnant during the study or within 90 days after the last dose of the study drug\n* Male participants with a female partner who is pregnant, nursing, or planning to become pregnant during the study or within 90 days after the last dose of the study drug\n\nOther protocol defined Inclusion\u002FExclusion criteria may apply.",true,"ALL","18 Years","55 Years",{"count":58,"type":59},18,"ACTUAL","INTERVENTIONAL",[62],"PHASE1","The purpose of this study is to evaluate the effect of multiple doses of vanzacaftor\u002Ftezacaftor\u002Fdeutivacaftor (VNZ\u002FTEZ\u002FD-IVA) on the PK of rosuvastatin and the safety and tolerability of coadministration of VNZ\u002FTEZ\u002FD-IVA with rosuvastatin.",[65],"Cystic Fibrosis","COMPLETED","2026-03-27",{"date":69,"type":59},"2026-04-02",{"date":71,"type":59},"2026-01-12",{"date":73,"type":59},"2026-03-12",{"name":5,"class":6},1]